Abstract
Transient lymphopenia is a common feature of acute viral respiratory infections1. The drastic and prolonged lymphopenia of COVID-19, however, is distinctive and largely stems from falling counts of T cells2-5. This T-cell lymphopenia may contribute to the inordinate rise in COVID-19 mortality with older age6, because naïve T-cell clonal expansion is telomere length (TL)-dependent7 and TL of hematopoietic cells shortens with age 8. Here we present a biologically plausible model that links naïve T-cell clonal expansion capacity and age-dependent hematopoietic cell TL (HCTL) shortening to explain the T-cell shortfall and the high COVID-19 mortality in older adults. The model shows that an individual with average HCTL at age twenty years maintains maximal T-cell clonal expansion capacity until the 6th decade of life when this capacity plummets by more than 90% over the next eight years. The collapse coincides with the steep increase in COVID-19 mortality with age. As young adults tend to maintain their relative HCTL over their life course9, individuals with above and below average HCTL respectively experience the drop in maximal T-cell clonal expansion capacity at older and younger ages. HCTL metrics may thus explain the vulnerability of older adults to COVID-19 and predict the capacity for T-cell clonal expansion following vaccination against the virus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AIY and KGA research is supported by NIH grant RF1AG046860. SV human telomere research is funded NIH grant 5U24AG066528. AA telomere research is supported by NIH grants R01 HL134840, U01AG066529 and a grant from the Norwegian Research Council (NFR) ES562296.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no approval required since paper uses publicly available date published
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in paper is available in supplemental material
